company background image
PKTX logo

ProtoKinetix OTCPK:PKTX Stock Report

Last Price

US$0.015

Market Cap

US$5.1m

7D

-26.1%

1Y

-46.5%

Updated

27 Mar, 2024

Data

Company Financials

ProtoKinetix, Incorporated

OTCPK:PKTX Stock Report

Market Cap: US$5.1m

PKTX Stock Overview

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs).

PKTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ProtoKinetix, Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ProtoKinetix
Historical stock prices
Current Share PriceUS$0.015
52 Week HighUS$0.035
52 Week LowUS$0.01
Beta-0.11
1 Month Change-26.50%
3 Month Change-24.23%
1 Year Change-46.55%
3 Year Change-92.83%
5 Year Change-80.96%
Change since IPO267.50%

Recent News & Updates

Recent updates

Shareholder Returns

PKTXUS BiotechsUS Market
7D-26.1%-0.5%0.6%
1Y-46.5%9.6%29.5%

Return vs Industry: PKTX underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: PKTX underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is PKTX's price volatile compared to industry and market?
PKTX volatility
PKTX Average Weekly Movement28.4%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: PKTX's share price has been volatile over the past 3 months.

Volatility Over Time: PKTX's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1999n/aClarence Smithhttps://www.protokinetix.com

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company’s AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases.

ProtoKinetix, Incorporated Fundamentals Summary

How do ProtoKinetix's earnings and revenue compare to its market cap?
PKTX fundamental statistics
Market capUS$5.10m
Earnings (TTM)-US$886.66k
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PKTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$886.66k
Earnings-US$886.66k

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0026
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PKTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.